Decreased voluntary activity and amygdala levels of serotonin and dopamine in ovariectomized rats

Izumo, Nobuo; Ishibashi, Yutaka; Ohba, Masashi; Morikawa, Tomomi; Manabe, Takayuki

doi:10.1016/j.bbr.2011.10.031

Cited by 45 publications

(40 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, the 5-HT levels in the amygdala were significantly decreased in OVX rats compared with those in sham-operated rats. These findings were consistent with our previous reports and suggested that our experimental model rats exhibited various mental processes and diseases such as fear, anxiety, depression, and schizophrenia [11,29].…”

Section: Discussionsupporting

confidence: 94%

“…Our previous study already demonstrated that the experimental conditions used in the present study did not produce any significant differences in the body weights of OVX and sham-operated rats at 2 W, while the body weights of OVX rats at 6 W were significantly higher than those of sham-operated rats [11], consistent with a previous report [28]. These observations indicate that our OVX experiments were appropriate.…”

Section: Discussionsupporting

confidence: 92%

“…The voluntary activity of OVX rats was significantly lower than that of sham-operated rats ( Figure 2A and B, sham and OVX). These data closely resemble the findings of our previous reports [11,29]. The decreased locomotor activity in OVX rats was significantly recovered by administration of 100 and 300 µg/kg MU314 ( Figure 2A and B, OVX and OVX-MU314).…”

Section: Spontaneous Locomotor Activitysupporting

confidence: 91%

“…More potent decreases in the levels of serotonin release in the amygdala were observed in OVX rats compared with those in sham-operated rats ( Figure 4A and B, sham and OVX), consistent with our previous studies [11,29]. These decreases in the serotonin levels in the amygdala were reversed by MU314 treatment in a dose-dependent manner ( Figure 4A and B, OVX and OVX-MU314).…”

Section: Serotonin Release In the Amygdalasupporting

confidence: 91%

“…Moreover, MU314 treatment increased and decreased the expression levels of tryptophan synthase (Tph) and 5-HT1a, respectively. These findings suggest the possibility that MU314 may increase serotonin release by activating the serotonin synthase Tph, followed by and microdialysis experiments were carried out in accordance with previous reports [11,29].…”

Section: Introductionsupporting

confidence: 87%

See 4 more Smart Citations

MU314, a novel selective estrogen receptor modulator (SERM), improves estrogen-dependent depressive behaviors

Izumo¹,

Ishibashi²,

Ono³

et al. 2017

Glob Drugs Therap

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 94%

Section: Discussionsupporting

confidence: 92%

Section: Spontaneous Locomotor Activitysupporting

confidence: 91%

Section: Serotonin Release In the Amygdalasupporting

confidence: 91%

Section: Introductionsupporting

confidence: 87%

See 3 more Smart Citations

MU314, a novel selective estrogen receptor modulator (SERM), improves estrogen-dependent depressive behaviors

Izumo¹,

Ishibashi²,

Ono³

et al. 2017

Glob Drugs Therap

View full text Add to dashboard Cite

Characterization of cachexia in the human fibrosarcoma HT‐1080 mouse tumour model

Bernardo

Joaquim

Garren

et al. 2020

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

Background Cancer cachexia is a complex metabolic disease with unmet medical need. Although many rodent models are available, none are identical to the human disease. Therefore, the development of new preclinical models that simulate some of the physiological, biochemical, and clinical characteristics of the human disease is valuable. The HT-1080 human fibrosarcoma tumour cell line was reported to induce cachexia in mice. Therefore, the purpose of this work was to determine how well the HT-1080 tumour model could recapitulate human cachexia and to examine its technical performance. Furthermore, the efficacy of ghrelin receptor activation via anamorelin treatment was evaluated, because it is one of few clinically validated mechanisms. Methods Female severe combined immunodeficient mice were implanted subcutaneously or heterotopically (renal capsule) with HT-1080 tumour cells. The cachectic phenotype was evaluated during tumour development, including body weight, body composition, food intake, muscle function (force and fatigue), grip strength, and physical activity measurements. Heterotopic and subcutaneous tumour histology was also compared. Energy balance was evaluated at standard and thermoneutral housing temperatures in the subcutaneous model. The effect of anamorelin (ghrelin analogue) treatment was also examined. Results The HT-1080 tumour model had excellent technical performance and was reproducible across multiple experimental conditions. Heterotopic and subcutaneous tumour cell implantation resulted in similar cachexia phenotypes independent of housing temperature. Tumour weight and histology was comparable between both routes of administration with minimal inflammation. Subcutaneous HT-1080 tumour-bearing mice presented with weight loss (decreased fat mass and skeletal muscle mass/fibre cross-sectional area), reduced food intake, impaired muscle function (reduced force and grip strength), and decreased spontaneous activity and voluntary wheel running. Key circulating inflammatory biomarkers were produced by the tumour, including growth differentiation factor 15, Activin A, interleukin 6, and TNF alpha. Anamorelin prevented but did not reverse anorexia and weight loss in the subcutaneous model. Conclusions The subcutaneous HT-1080 tumour model displays many of the perturbations of energy balance and physical performance described in human cachexia, consistent with the production of key inflammatory factors. Anamorelin was most effective when administered early in disease progression. The HT-1080 tumour model is valuable for studying potential therapeutic targets for the treatment of cachexia.

show abstract

Sex‐dependent differences in voluntary physical activity

Rosenfeld

2016

J of Neuroscience Research

122

View full text Add to dashboard Cite

There are increasing numbers of overweight and obese individuals in the US and globally, and correspondingly, the associated healthcare costs are rising dramatically. More than one-third of children are currently considered obese with a predisposition to type 2 diabetes, and it is likely that their metabolic conditions will worsen with age. Physical inactivity has also risen to be the leading cause of many chronic, non-communicable diseases (NCD). Children are more physically inactive now than they were in past decades, which may be due to intrinsic and extrinsic factors. In rodents, the amount of time engaged in spontaneous activity within the home cage is a strong predictor of later adiposity and weight gain. Thus, it is important to understand primary motivators stimulating physical activity (PA). There are normal sex differences in PA levels in rodents and humans. The perinatal environment can induce sex-dependent differences in PA disturbances. This review will consider the current evidence that there are sex differences in PA in rodents and humans. The rodent studies showing that early exposure to environmental chemicals can shape later adult PA responses will be discussed. Next, an exploration of whether there are different motivators stimulating exercise in male vs. female humans will be examined. Finally, the brain regions, genes, and pathways, that modulate PA in rodents, and possibly by translation humans, will be described. A better understanding of why each sex remains physically active through the lifespan could open up new avenues to prevent and treat obesity in children and adults.

show abstract

Decreased voluntary activity and amygdala levels of serotonin and dopamine in ovariectomized rats

Cited by 45 publications

References 54 publications

MU314, a novel selective estrogen receptor modulator (SERM), improves estrogen-dependent depressive behaviors

MU314, a novel selective estrogen receptor modulator (SERM), improves estrogen-dependent depressive behaviors

Characterization of cachexia in the human fibrosarcoma HT‐1080 mouse tumour model

Sex‐dependent differences in voluntary physical activity

Contact Info

Product

Resources

About